These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 34442417)
21. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604 [TBL] [Abstract][Full Text] [Related]
22. Personalized Medicine in Parkinson's Disease: New Options for Advanced Treatments. Mishima T; Fujioka S; Morishita T; Inoue T; Tsuboi Y J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357117 [TBL] [Abstract][Full Text] [Related]
23. Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty. Auffret M; Weiss D; Stocchi F; Vérin M; Jost WH J Neural Transm (Vienna); 2023 Nov; 130(11):1411-1432. PubMed ID: 37436446 [TBL] [Abstract][Full Text] [Related]
24. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Antonini A; Yegin A; Preda C; Bergmann L; Poewe W; Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993 [TBL] [Abstract][Full Text] [Related]
25. Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis. Nijhuis FAP; Esselink R; de Bie RMA; Groenewoud H; Bloem BR; Post B; Meinders MJ Mov Disord; 2021 Jun; 36(6):1293-1307. PubMed ID: 33797786 [TBL] [Abstract][Full Text] [Related]
28. Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review. Boura I; Haliasos N; Giannopoulou ΙA; Karabetsos D; Spanaki C Mov Disord Clin Pract; 2021 Jul; 8(5):750-757. PubMed ID: 34307748 [TBL] [Abstract][Full Text] [Related]
29. [Decision-making and duration to accept device-aided therapy in advanced Parkinson’s disease]. Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Frigy A; Nagy E; Kelemen K; Forró T; Almásy E; Orbán-Kis K Orv Hetil; 2021 May; 162(21):839-847. PubMed ID: 34023813 [TBL] [Abstract][Full Text] [Related]
30. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population. Antonini A; Marano P; Gusmaroli G; Modugno N; Pacchetti C; Sensi M; Melzi G; Bergmann L; Zibetti M; Lopiano L Neurol Sci; 2020 Oct; 41(10):2929-2937. PubMed ID: 32342325 [TBL] [Abstract][Full Text] [Related]
32. What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience. Phokaewvarangkul O; Auffret M; Groppa S; Markovic V; Petrovic I; Bhidayasiri R J Neural Transm (Vienna); 2024 Nov; 131(11):1307-1320. PubMed ID: 38747986 [TBL] [Abstract][Full Text] [Related]
34. [Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary]. Nagy H; Takáts A; Tóth A; Bereczki D; Klivényi P; Dézsi L; Dibó G; Vécsei L; Kovács N; Aschermann Z; Komoly S; Varannai L; Zemlényi G; Valikovics A Ideggyogy Sz; 2014 Nov; 67(11-12):385-9. PubMed ID: 25720240 [TBL] [Abstract][Full Text] [Related]
35. Medical and surgical management of advanced Parkinson's disease. Antonini A; Moro E; Godeiro C; Reichmann H Mov Disord; 2018 Jul; 33(6):900-908. PubMed ID: 29570862 [TBL] [Abstract][Full Text] [Related]
36. Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease. Hoy SM Drugs; 2019 Oct; 79(15):1709-1718. PubMed ID: 31549300 [TBL] [Abstract][Full Text] [Related]
37. Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy. Sahlström T; Eklund M; Timpka J; Henriksen T; Nyholm D; Odin P Acta Neurol Scand; 2018 Jul; 138(1):78-84. PubMed ID: 29569237 [TBL] [Abstract][Full Text] [Related]
38. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635 [TBL] [Abstract][Full Text] [Related]
39. Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. Liu XD; Bao Y; Liu GJ Front Neurol; 2019; 10():934. PubMed ID: 31507529 [No Abstract] [Full Text] [Related]
40. The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review. Chan GH Front Aging Neurosci; 2022; 14():895430. PubMed ID: 35754954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]